Key result
Lidocaine required large doses (≥5 × 10(-4) mol/l) to inhibit action potentials in single cardiac cells, whereas much lower therapeutic doses (5 × 10(-6) mol/l) were sufficient in papillary muscles.
Why the study?
Does lidocaine cause rate-dependent activation failure differently in isolated cardiac cells compared to multicellular tissue?
Does lidocaine cause rate-dependent activation failure differently in isolated cardiac cells compared to multicellular tissue?
Answers are grounded in this paper and cite their sources.
The syncytial nature of cardiac tissue explains why clinically relevant, low doses of Na+ channel blockers cause conduction block, whereas isolated cells require hundredfold higher doses.
While it is well established that class-I antiarrhythmics block cardiac sodium channels, the mechanism of action of therapeutic levels of these drugs is not well understood. Using a combination of mathematical modeling and in vitro experiments, we studied the failure of activation of action potentials in single ventricular cells and in tissue caused by Na(+) channel block. Our computations of block and unblock of sodium channels by a theoretical class-Ib antiarrhythmic agent predict differences in the concentrations required to cause activation failure in single cells as opposed to multicellular preparations. We tested and confirmed these in silico predictions with in vitro experiments on isolated guinea-pig ventricular cells and papillary muscles stimulated at various rates (2-6.67 Hz) and exposed to various concentrations (5 × 10(-6) to 500 × 10(-6) mol/l) of lidocaine. The most salient result was that whereas large doses (5 × 10(-4) mol/l or higher) of lidocaine were required to inhibit action potentials temporarily in single cells, much lower doses (5 × 10(-6) mol/l), i.e., therapeutic levels, were sufficient to have the same effect in papillary muscles: a hundredfold difference. Our experimental results and mathematical analysis indicate that the syncytial nature of cardiac tissue explains the effects of clinically relevant doses of Na(+) channel blockers.
No takes yet. Share an insight, caveat, or question.
Varghese et al. (2015) studied this question. Lidocaine was evaluated on Activation failure of action potentials. Lidocaine required large doses (≥5 × 10(-4) mol/l) to inhibit action potentials in single cardiac cells, whereas much lower therapeutic doses (5 × 10(-6) mol/l) were sufficient in papillary muscles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: